Charlotte Robinson

DocwireNews

Following the presentation of <a href="https://www.docwirenews.com/post/origin-study-of-atacicept-for-iga-nephropathy">interim study results</a> at the 61st European Renal Association Congress, Vera Therapeutics announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its drug atacicept to treat IgA nephropathy (IgAN).The designation, which will expedite the development and review of the drug, was based on an assessment of data from the phase 2b ORIGIN clinical trial of atacicept for IgAN, which showed the stabilization of estimated glomerular filtration rate (eGFR) over 72 weeks of treatment. Study participants received atacicept in a 36-week double-blind period, then continued to receive atacicept 150 mg self-administered subcutaneously once weekly at home during 36 additional weeks of open-label follow-up.The eGFR stabilization aligned with an eGFR profile more consistent with that of the general population rather than patients presenting with IgAN. Vera believes eGFR stabilization with atacicept marks a substantial potential improvement over current therapies. The company stated that it plans to announce 96-week results from the phase 2b ORIGIN trial later this year and expects primary end point results from the phase 3 ORIGIN 3 trial to be revealed in the first half of 2025 to support submission for regulatory approval of atacicept in IgAN.ORIGIN 3 will evaluate the safety and efficacy of atacicept 150 mg in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite being on a stable prescribed regimen of renin-angiotensin system inhibitors for at least 12 weeks at the maximum labeled or tolerated dose. The primary end point is the change from baseline in proteinuria as evaluated by urine protein-to-creatinine ratio at week 36.

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

FDA Grants Breakthrough Designation to Atacicept for IgA Nephropathy

IgA Nephropathy

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to atacicept to treat IgA nephropathy (IgAN).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe